Clinical Trial: The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational [Patient Registry]
Official Title:
Brief Summary: This study investigates the relationship of circulating microRNA-30e and schizophrenia, and shows the relevance of the aberrant microRNA-30e expression in plasma with the variation disease status.
Detailed Summary:
The plasma samples from 15 individuals with schizophrenia (with a diagnosis of ICD-10) and the equivalent healthy controls will be conducted with the quantification analysis of the microRNA-30e via real-time quantitative polymerase chain reaction(RT-PCR).
The 15 patients enrolled should be the first-episode and have not been treated, or were drug free 3 months recently at least.
This research measures the expression level of microRNA-30e in schizophrenia respectively before the beginning treatment with atypical psychotics or combined with MECT, after the 4-week treated , the 8-week treated compared with 15 healthy controls.
Sponsor: Dalian Seventh People's Hospital
Current Primary Outcome:
- the Baseline expression profiling of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR) [ Time Frame: before the treatment ]the plasma samples will be collected from the patients with schizophrenia and the healthy controls at the beginning recruit for the microRNA-30e detection
- the Changed expression level of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR) [ Time Frame: Change from Baseline expression level at 4-week treatment ]the plasma samples will be collected from the patients with schizophrenia at the 4-week treatment for the microRNA-30e detection
- the Changed expression level of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR) [ Time Frame: Change from Baseline expression level at 8-week treatment ]the plasma samples will be collected from the patients with schizophrenia at the 8-week treatment for the microRNA-30e detection
Original Primary Outcome: Same as current
Current Secondary Outcome:
- the scores of Positive and Negative Syndrome Scale(PANSS) for the patients with schizophrenia [ Time Frame: before, after 4 weeks and 8 weeks treatment ]The PANSS for estimating the severity of positive and negative symptoms in schizophrenia
- The degree of Personal and Social Performance scale(PSP) for the patients with schizophrenia [ Time Frame: before, after 4 weeks and 8 weeks treatment ]The degree of Personal and Social Performance scale(PSP) used to evaluate the disable levels in Multiple dimensions ,especially in social and self-care performance
- The scale of Clinical Global Impression(CGI) in patients with schizophrenia after treatment [ Time Frame: 4 weeks and 8 weeks treatment ]Main purpose to provide a global rating of illness severity ,improvement and response to treatment for the patients with schizophrenia
Original Secondary Outcome: Same as current
Information By: Dalian Seventh People's Hospital
Dates:
Date Received: November 17, 2016
Date Started: June 2016
Date Completion: July 2017
Last Updated: December 28, 2016
Last Verified: December 2016